

1. Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P. 5'-Nor anhydrovinblastine, prototype of a new class of vinblastine derivatives. *Tetrahedron* 1979, **35**, 2175-2179.
2. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier, Meininger V. *In situ* analysis of the action of Navelbine® on various types of microtubules using immunofluorescence. *Semin Oncol* 1989, **16** (Suppl. 4), 5-8.
3. Monnet I, Azli N, Voisin S, *et al.* 5-fluorouracil/leucovorin/vindesine/cisplatin in non-small cell lung cancer: a phase II study. *Proc Am Soc Clin Oncol* 1991, **10**, A 879.
4. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. *J Clin Oncol* 1989, **7**, 425-432.
5. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. *Cancer* 1989, **63**, 1036-1044.
6. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group Study. *Cancer* 1989, **63**, 1026-1030.
7. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. Efficacy of Navelbine® (NVB) in non small cell lung cancer (NSCLC). *Semin Oncol* 1989, **16** (Suppl. 4), 26-29.
8. Besenval M, Delgado M, Demarez JP, Krikorian A. Safety and tolerance of Navelbine in phase I-II clinical studies. *Semin Oncol* 1989, **16** (Suppl. 4), 37-40.
9. Canobbio L, Boccardo F, Guarneri D, *et al.* Phase II study of navelbine in advanced renal cell carcinoma. *Eur J Cancer* 1991, **27**, 804-805.
10. Dieras V, Varette C, Louvet C, Espié M, Colin P, Marty M. Association Navelbine® -5-fluoro-uracile dans le traitement de première intention d'adénocarcinomes mammaires métastatiques. In: Solal-Celigny P, ed. *Navelbine: Actualités et Perspectives*. London, John Libbey, 1990, 225-231.

## Corrections

**Cancer in the European Community and its member states.** — In this article by Dr O. Møller Jensen *et al.* (Vol. 26, 1167-1256), the number of new cases of cancer in the Summary and on p. 1171 should have read 1222 120 and not 1186 000. The same applies to the accompanying editorial by C.S. Muir and P. Boyle (p. 1112).

**Intraperitoneal chemotherapy for malignant peritoneal mesothelioma.** — In this article by Dr L.Th. Vlasveld *et al.* (Vol. 27, 732-734), the fifth sentence of the final paragraph of the discussion should have begun: "Furthermore, the data presented in Tables 1 and 2..."

**Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for *in vitro* chemosensitivity testing.** — In this article by Dr Y.P. Keepers *et al.* (Vol. 27, 897-900), the units for IC<sub>50</sub> in Table 1 should have been  $\mu\text{mol/l}$ .

**Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.** — In this article by Dr N.W. Marschner *et al.* (Vol. 27, 1137-1140) the references should have read as follows:

1. Canellos GP, De Vita VT, Gold GL, *et al.* Combination chemotherapy for advanced breast cancer: response and effect on survival. *Ann Intern Med* 1976, **84**, 389-392.
2. Hortobagyi GN, Bodey GP, Budzar AU, *et al.* Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer

in protected environment units: A prospective randomised study. *J Clin Oncol* 1987, **5**, 354-364.

3. Wilcox PM, Fetting JH, Nettlesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy for breast carcinoma. *Cancer Treat Rep* 1982, **66**, 1601-1604.
4. Gralla RJ, Tyson LB, Kris MG, Clark RA. The management of chemotherapy induced nausea and vomiting. *Med Clin North Am* 1987, **71**, 289-301.
5. Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, Del Favero A. Double-blind controlled trial of the anti-emetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with CMF. *Eur J Cancer Clin Oncol* 1987, **23**, 615-617.
6. Cunningham D, Evans C, Gazet J-C, *et al.* Comparison of anti-emetic efficacy of domperidone, metoclopramide and dexamethasone in patients receiving outpatient chemotherapy regimens. *Br Med J* 1987, **295**, 250.
7. Cunningham D, Pople A, Ford HT, *et al.* Prevention of emesis in patients receiving cyto antagonists. *Lancet* 1987, 1461-1463.
8. Cox R, Newman CE, Leyland MJ. Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy. *Cancer Chemother Pharmacol* 1982, **8**, 133-135.
9. Gralla RJ. Metoclopramide. A review of anti-emetic trials. *Drugs* 1983, **25** (Suppl. 1), 63-73.
10. Grunberg SM, Akerley WL, Krailo MD, *et al.* Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatin-induced emesis. *Cancer Invest* 1986, **4**, 379-385.
11. Gunning SJ, Hagan RM, Tyers MB. Cisplatin induces biochemical and histological changes in the small intestine of the ferret. *Br J Pharmacol* 1987, **90**, 135P.
12. Cubeddu L, Hoffmann I, Fuenmajor M, Finn AL. Ondansetron, an antagonist of serotonin 5-HT-3 receptors prevents vomiting induced by cisplatin- and cyclophosphamide containing chemotherapy regimens. *Proc Am Soc Clin Oncol* 1990, Abstr 1281.
13. Andrews PLR, Hawthorn J, Sanger GJ. The effect of abdominal visceral nerve lesions and a novel 5-HT-3 receptor antagonist on cytotoxic and radiation induced emesis in the ferret. *J Physiol* 1986, **382**, 47P.
14. Tyers MB, Bunce KT, Humphrey PP. Pharmacological and anti-emetic properties of ondansetron. *Eur J Cancer Clin Oncol* 1989, **25** (Suppl. 1), 15-19.
15. Einhorn LH, Nagy C, Werner K, Finn AL. Ondansetron: A new anti-emetic for patients receiving cisplatin chemotherapy. *J Clin Oncol* 1990, **8**, 731-735.
16. Bonnetterre J, Chevallier B, Metz R, *et al.* A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. *J Clin Oncol* 1990, **8**, 1063-1069.
17. Kaasa S, Kvaloy SL, Dicato MA, Ries F, Huys JV, Royer E, Carruthers and the International Emesis Group. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. *Eur J Cancer* 1990, **26**, 311-314.
18. Priestman TJ. Clinical studies with ondansetron in the control of radiation induced emesis. *Eur J Cancer Clin Oncol* 1989, **25** (Suppl. 1), 29-33.
19. Marschner NW, Nagel GA, Brunsch U, *et al.* Oral GR38072F as anti-emetic prophylaxis in patients receiving cyclophosphamide containing chemotherapy regimens. *Cancer Chemother Pharmacol* 1989, **23** (Suppl), Abstr. 266(P).
20. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel Haenszel procedure. *J Am Stat Association* 1963, **58**, 690-700.
21. Pendergrass K, Hainsworth J, Harvey W, Kasimis B, Finn A. Ondansetron (OND): more effective than metoclopramide (MCP) in the prevention of cisplatin (DDP)-induced nausea (N) and vomiting (V). *Proc ASCO* 1990, Abstr 1234.

**Report on consensus meeting of the EORTC Melanoma Group on educational needs for primary and secondary prevention of melanoma in Europe.** — In this article by Dr R.M. Mackie *et al.* (Vol. 27, 1317-1323), Dr Kölmel's address was wrongly ascribed as Göttingen, The Netherlands. The correct country is F.R.G.